)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Iconovo
Iconovo (ICO) investor relations material
Iconovo Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary23 Oct, 2026
Executive summary
Licensing discussions for ICOres and ICOpre advanced; securing at least one near-term agreement remains critical to commercial progress and financing.
Net sales rose sharply on development income, while operating losses narrowed and costs remained under tight control.
Financial highlights
Q3 net sales were TSEK 707 vs 7; 9M net sales increased 219% to TSEK 1,917 vs 601, exceeding FY2025 sales by 73%.
Q3 operating loss narrowed to TSEK 6,770 vs 8,828; 9M operating loss improved to TSEK 24,081 vs 30,173.
Net loss was TSEK 6,809 in Q3 vs 8,863 and TSEK 24,274 in 9M vs 30,396.
9M total costs declined 15% to TSEK 29,155; personnel costs fell 34% to TSEK 14,312, while raw-material costs rose to TSEK 4,213 from 1,933.
Outlook and guidance
Management aims to conclude at least one ICOres or ICOpre partner discussion in the near term; successful transactions are expected to materially support revenue and financing.
Based on budgets and business outlook, sufficient funding is expected for the next 12 months if anticipated near-term transactions are finalized successfully.
Oxytocin development for postpartum haemorrhage awaits a Gates Foundation funding decision; GLP-1 preclinical work was scheduled for evaluation later in autumn 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Iconovo
- Announced 36.6 MSEK rights issue, investor presentation, and focus on inhaled generics.ICO
Investor update - Improved financials and strategic partnerships set the stage for growth, pending key licensing deals.ICOQ2 2026
- Net sales grew 45% and losses narrowed, with financing secured and strategic partnerships advancing.ICOQ1 2026
- Declining sales and losses prompt capital raise and strategic shift toward partnerships and GLP-1 projects.ICOQ4 2025
- Strategic refocus and cost cuts in Q3 2025 position for growth in inhalers and semaglutide.ICOQ3 2025
- Restructuring and capital raise position the company for commercialization despite lower sales.ICOQ2 2025
- No Q3 revenue; key inhaler projects advanced, rights issue to fund next phase.ICOQ3 2024
- Strategic progress in inhaler IP, licensing, and obesity drug reformulation, with improved losses.ICOQ2 2024
- Iconovo pivots to commercialization, secures funding, and advances inhalable drug partnerships.ICOQ1 2025
Next Iconovo earnings date
Q4 202626 Feb, 2027
Iconovo
Next Iconovo earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Iconovo AB develops and licenses inhalation devices for inhaled medicine. The company’s product portfolio includes the Icon, a disposable handheld inhaler, which is a solution for respiratory diseases; Clickhaler, a drug delivery inhaler that is used to treat respiratory airways inflammation and asthma; and Easyhaler, a powder inhaler that is used for the treatment of asthma and chronic obstructive pulmonary disease.